Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer

Background: The incidence and mortality of breast cancer are increasing annually. Breast cancer seriously threatens women's health and quality of life. We aimed to measure the clinical value of CPN1, a new serum marker of breast cancer and to evaluate the efficacy of CPN1 in combination with CA15-3. Methods: Seventy samples of breast cancer with lymph node metastasis, seventy-three samples of nonmetastatic breast cancer and twenty-five samples of healthy human serum were collected. Serum CA15-3 concentration was determined by Roche Elecsys, and serum CPN1 concentration was determined by ELISA. Results: In breast cancer patients, serum CPN1 concentration was positively correlated with tumour size, clinical stage and CA15-3 concentration (r = 0.376, P<0.0001). ROC curve analysis showed that the optimal critical concentration of CPN1 for breast cancer diagnosis was 32.8pg/ml. The optimal critical concentration of CPN1 in the diagnosis of metastatic breast cancer was 66.121pg/ml. CPN1 has a greater diagnostic ability for breast cancer (AUCCA15-3=0.702 vs. AUCCPN1=0.886, P<0.0001) and metastatic breast cancer (AUCCA15-3=0.629 vs. AUCCPN1=0.887, P<0.0001) than CA15-3, and the combined detection of CA15-3 and CPN1 can improve the diagnostic efficiency for breast cancer (AUCCA15-3+CPN1=0.916) and for distinguishing between metastatic and non-metastatic breast cancer (AUCCA15-3+CPN1=0.895). Conclusion: CPN1 can be used as a new tumour marker to diagnose and evaluate the invasion and metastasis of breast cancer. The combined detection of CPN1 and CA15-3 is more accurate and has a certain value in clinical application.

Download Full-text

A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China

Scientific Reports ◽

10.1038/s41598-021-93350-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yujing Xin ◽

Xinyuan Zhang ◽

Yi Yang ◽

Yi Chen ◽

Yanan Wang ◽

...

Keyword(s):

Breast Cancer ◽

False Negative ◽

Final Analysis ◽

Age Group ◽

Surgical Biopsy ◽

True Negative ◽

Diagnostic Efficacy ◽

Negative Results ◽

Informed Consent Form ◽

Magnetic Resonance Imaging Mri

AbstractThis study is the first multi-center non-inferiority study that aims to critically evaluate the effectiveness of HHUS/ABUS in China breast cancer detection. This was a multicenter hospital-based study. Five hospitals participated in this study. Women (30–69 years old) with defined criteria were invited for breast examination by HHUS, ABUS or/and mammography. For BI-RADS category 3, an additional magnetic resonance imaging (MRI) test was provided to distinguish the true negative results from false negative results. For women classified as BI-RADS category 4 or 5, either core aspiration biopsy or surgical biopsy was done to confirm the diagnosis. Between February 2016 and March 2017, 2844 women signed the informed consent form, and 1947 of them involved in final analysis (680 were 30 to 39 years old, 1267 were 40 to 69 years old).For all participants, ABUS sensitivity (91.81%) compared with HHUS sensitivity (94.70%) with non-inferior Z tests, P = 0.015. In the 40–69 age group, non-inferior Z tests showed that ABUS sensitivity (93.01%) was non-inferior to MG sensitivity (86.02%) with P < 0.001 and HHUS sensitivity (95.44%) was non-inferior to MG sensitivity (86.02%) with P < 0.001. Sensitivity of ABUS and HHUS are all superior to that of MG with P < 0.001 by superior test.For all participants, ABUS specificity (92.89%) was non-inferior to HHUS specificity (89.36%) with P < 0.001. Superiority test show that specificity of ABUS was superior to that of HHUS with P < 0.001. In the 40–69 age group, ABUS specificity (92.86%) was non-inferior to MG specificity (91.68%) with P < 0.001 and HHUS specificity (89.55%) was non-inferior to MG specificity (91.68%) with P < 0.001. ABUS is not superior to MG with P = 0.114 by superior test. The sensitivity of ABUS/HHUS is superior to that of MG. The specificity of ABUS/HHUS is non-inferior to that of MG. In China, for an experienced US radiologist, both HHUS and ABUS have better diagnostic efficacy than MG in symptomatic individuals.

Download Full-text

The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer

10.21203/rs.2.15310/v1 ◽

2019 ◽

Author(s):

Gongpan Liu ◽

Cunhua Shao ◽

Anyun Li ◽

Xiaobin Zhang ◽

Xingjun Guo ◽

...

Keyword(s):

Pancreatic Cancer ◽

Early Diagnosis ◽

Operating Characteristic ◽

Clinical Stage ◽

Diagnostic Value ◽

Carbohydrate Antigen ◽

Healthy Individuals ◽

Diagnostic Efficacy ◽

Lymph Nodes Metastasis ◽

Combined Detection

Abstract Background This study aimed to investigate the effect of combination of plasma miR-181b, miR-196a and miR-210 on early diagnosis of pancreatic cancer (PC).Methods In our study, the plasma was isolated from patients with PC and healthy individuals, respectively. The expressions of miR-181b, miR-196a and miR-210 were detected by qRT-PCR. Moreover, the level of carbohydrate antigen 199 (CA199) was measured by electrochemiluminescence (ECL) assay. Furthermore, the area under the receiver operating characteristic (ROC) curve (AUC) was used to analyze the diagnostic efficacy of miR-181b, miR-196a, miR-210 and CA199, as well as the combination of thses miRNAs in early PC patients and healthy individuals.Results The expressions of miR-181b, miR-196a and miR-210 were significantly upregulated in PC patients. In addition, the level of CA199 was also significantly upregulated in the plasma of PC patients. The expressions of miR-181b, miR-196a and miR-210 were closely associated with lymph nodes metastasis, clinical stage and vascular invasion, but had no correlation with the patient's age, gender and tumor size. Moreover, miR-181b, miR-196a and miR-210 have lower AUC than CA199 in PC patients. The combinations miR-181b + miR-196a, miR-181b + miR-210, miR-196a + miR-210 also have lower AUC than CA199 in PC patients. It is worth noting that the combinations miR-181b + miR-196a + miR-210 have higher AUC than CA199 in PC.Conclusions Our study demonstrated that the combination of plasma miR-181b, miR-196a and miR-210 had good value for PC early diagnosis.

Download Full-text

Long Noncoding RNA Serve as a Potential Predictive Biomarker for Breast Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2020/9045786 ◽

2020 ◽

Vol 2020 ◽

pp. 1-15

Author(s):

Xuefeng Jiang ◽

Guijuan Zhang ◽

Jieyan Wu ◽

Shujun Lin ◽

Yusheng Liu ◽

...

Keyword(s):

Breast Cancer ◽

Long Noncoding Rna ◽

Noncoding Rna ◽

Meta Analysis ◽

Characteristic Curve ◽

Breast Cancer Diagnosis ◽

Predictive Biomarker ◽

Cochrane Library ◽

Summary Receiver Operating Characteristic ◽

Diagnostic Efficacy

Purpose. The detection of long noncoding RNA (lncRNA) is a novel method for breast cancer diagnosis. The purpose of this meta-analysis was to evaluate the clinical significance of lncRNAs in identification of human breast cancer. Methods. Electronic databases, including PubMed (176), EMBASE (167), Cochrane Library (4), Web of Science (273), CNKI (41), VIP (18), and wanfang (21), were searched for relevant original articles. Diagnostic capacity of lncRNAs was assessed by pooled sensitivity and specificity, area under the summary receiver operating characteristic curve (AUC), diagnostic odds ratio (DOR), and subgroup and meta-regression analysis. Stata and Meta-Disc software were used to conduct the meta-analysis. Results. 33 articles including 4500 cases were identified in our meta-analysis. lncRNAs sustained a high diagnostic efficacy; the pooled sensitivity, specificity, AUC, and DOR of lncRNAs in differentiating BC from controls were 0.74 (95% CI: 0.69-0.78), 0.78 (95% CI: 0.72-0.83), 0.82 (95% CI: 0.79-0.85), and 10.01 (95% CI: 7.13-14.06), respectively. The subgroup analysis showed that the diagnostic efficacy of lncRNAs in Asian populations was higher than that in Caucasians; lncRNAs in BC were lower than those in TNBC and were higher in plasma and serum specimens than in tissues. In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. Conclusion. This meta-analysis suggested that lncRNAs might be promising biomarkers for identifying breast cancer, and its clinical application warrants further investigation.

Download Full-text

CA 15.3 with Urinary Calcium Excretion is Useful in the Diagnosis and Monitoring of Bone Metastases from Breast Cancer

The International Journal of Biological Markers ◽

10.1177/172460089300800402 ◽

1993 ◽

Vol 8 (4) ◽

pp. 208-214

Author(s):

G.C. Yadav ◽

A. Rao ◽

M.M. Motawy ◽

N. Safadi ◽

M. Jameel Ahmed

Keyword(s):

Breast Cancer ◽

Bone Metastasis ◽

Bone Metastases ◽

Serum Levels ◽

Urinary Calcium ◽

Response To Therapy ◽

Urinary Calcium Excretion ◽

Calcium Excretion ◽

Diagnostic Efficacy ◽

Ca 15.3

Serum levels of breast carcinoma antigen (CA 15.3) and urinary calcium excretion (UCa) were determined in 73 patients with breast cancer: 36 without bone metastases (stage I-IV) and 37 with bone metastases. The patients in the latter group were further investigated at 2,4 and 6 months from the start of treatment. Both markers showed significant elevations in the group with bone metastases (CA 15.3: P = 1.0×10–6, UCa: P = 8.6×10–9). The bone metastasis index (BMI), which represents the combination of the markers, had better diagnostic efficacy (90%) than CA 15.3 alone (84%) or UCa alone (82%). During treatment of bone metastasis, the longitudinal levels of the markers showed a highly significant association with the therapeutic response assessed by the UICC criteria. For identifying progression of disease, the diagnostic efficacy of CA 15.3, UCa and a combination of both, the so-called Biochemical Index of Response (BIR), was 65%, 70% and 79%, respectively, at two months and 89%, 84% and 92% at four months. Application of the tandem, CA 15.3 with UCa, was very useful for the detection of bone metastases and the prediction of response to therapy.

Download Full-text

Combined Detection of HER2, Ki67, and GSTP1 Genes on the Diagnosis and Prognosis of Breast Cancer

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2018.2570 ◽

2019 ◽

Vol 34 (2) ◽

pp. 85-90 ◽

Cited By ~ 3

Author(s):

Bo Song ◽

Lu Wang ◽

Yang Zhang ◽

Ning Li ◽

Hao Dai ◽

...

Keyword(s):

Breast Cancer ◽

Diagnosis And Prognosis ◽

Combined Detection ◽

Gstp1 Genes

Download Full-text

Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000000573 ◽

2016 ◽

Vol 37 (11) ◽

pp. 1180-1188 ◽

Cited By ~ 11

Author(s):

Yu Xiao ◽

Ling Wang ◽

Xuehua Jiang ◽

Wei She ◽

Li He ◽

...

Keyword(s):

Breast Cancer ◽

Fdg Pet ◽

Diagnostic Efficacy ◽

Pet Ct ◽

18F Fdg ◽

Suspected Recurrence

Download Full-text

Diagnostic value of various vascular features of breast cancer by age

Clinical Hemorheology and Microcirculation ◽

10.3233/ch-211258 ◽

2021 ◽

pp. 1-9

Author(s):

Jia Lin ◽

Wenqiang Lin ◽

Liang Xu ◽

Teng Lin

Keyword(s):

Breast Cancer ◽

Breast Imaging ◽

Critical Role ◽

Added Value ◽

Breast Lesions ◽

Diagnostic Efficiency ◽

Complex Flow ◽

Diagnostic Efficacy ◽

Breast Masses ◽

Malignant Breast

BACKGROUND: Tumor angiogenesis plays a critical role in the growth and metastasis of breast cancer and evaluating the added value of vascular features to Breast Imaging Reporting and Data System (BI-RADS) in differentiating malignant nodules from benign ones is essential. Micro-flow Imaging (MFI) is a promising noninvasive diagnostic method for the microvessels in breast tumors, but its precise value is still uncertain. OBJECTIVES: Understanding whether malignant tumor vascular characteristics by MFI are associated with breast cancer and whether the diagnostic efficiency varies by age. MATERIALS AND METHODS: We used B-mode Ultrasound and MFI to detect the characteristics of 153 solid breast lesions. Two investigators reviewed the vessels images by MFI and assessed the vascular features, respectively. Evaluating diagnostic efficacy of different vascular features combined with BI-RADS in different age groups. RESULTS: The mean size of lesions is 19.4 (range 18–78) mm. There were 94 breast masses in benign, while 59 breast masses in malignant by pathology. III Adler classification, penetrating vessels, and complex flow pattern showed a positive association with a high risk of malignant breast lesions (p < 0.05). BI-RADS combined with vessel characteristics show better improvement of diagnostic performance of breast lesions in the elderly group than in the young group. CONCLUSIONS: Vascular features by MFI contribute to malignant breast masses’ diagnosis, and the association might be modified by age.

Download Full-text